TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05221970

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online
Description: This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive Psychology - online
Description: This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Autogenic Training - online
Description: This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
Study: NCT06611618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle force assessment
Description: Isometric dynamometry (Maximal Voluntary Isometric Contraction)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based mobility monitoring
Description: Mobility monitoring with wearable sensors

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Full lower limb MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait assessment
Description: Motion capture, surface EMG and gorund reaction force data
Study: NCT05717725

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed-field ablation
Description: Patients will receive catheter ablation, i.e. pulmonary vein isolation by means of pulsed-field energy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Patients will receive sham procedure, no ablation.
Study: NCT06596668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbamazepine
Description: Oral extended-release capsule
Study: NCT05036798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Chemotherapy regimen:~Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2 Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD
Study: NCT06589414

Intervention type: OTHER
Group type: OTHER
Intervention: Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)
Description: A summary consultation with the patient's general practitioner (GP) will take place within 15 days of the consultation to announce the cancer diagnosis. This patient-general practitioner consultation will complement the initial consultation.~At the end of the summary consultation, the patient's satisfaction and that of the GP will be assessed using satisfaction questionnaires.~In addition, patients will be asked to complete a patient diary for the duration of their participation in the study (6 months), in order to record the dates of consultations with the GP and the dates of consultations and/or hospitalisations at the referral care centre.
Study: NCT05347485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Description: Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
Study: NCT06058793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigimadlin
Description: Brigimadlin
Study: NCT06676540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Therapy (NDT) and Eccentric Exercise Training Group (NDT+EE)
Description: Including Functional Eccentric Exercises Applied to Individuals with Cerebral Palsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy (NDT)
Description: This application includes rehabilitation methods frequently used in pediatric rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Therapy (NDT)
Description: This application includes rehabilitation methods frequently used in pediatric rehabilitation.
Study: NCT06362993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundling
Description: Education on and screening for diabetes and hypertension offered together with education and screening for breast cancer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEGH
Description: Education on breast cancer and discussion sessions to male partners to change men's gender attitudes and behaviors.
Study: NCT05398445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Participants will receive Rocatinlimab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Participants will receive Rocatinlimab subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo subcutaneously.
Study: NCT05211050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levcromakalim
Description: 20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: 20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: 10 min infusion of 4 mg sumatriptan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10 min infusion of isotonic saline (placebo).
Study: NCT04661137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 60 MG
Description: Selinexor 60 mg PO on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 80 MG
Description: Selinexor 80 mg PO on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 100 MG
Description: Selinexor 100 mg PO on days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 56 mg/m2 IV on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg PO daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22
Study: NCT06512922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adaptive cognitive training
Description: The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placebo cognitive training
Description: They received cognitive training tasks of fixed difficulty.
Study: NCT05694806

Intervention type: OTHER
Intervention: analysis of thoracic scans
Description: analysis of thoracic scans realised in standard care
Study: NCT05797441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: The goals of EMPOWER are to increase patients' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in TFT through the continued application of TFT skills, and encourage engagement in meaningful life activities. The program includes a Veteran workbook and four planned therapist contacts over the twelve weeks following TFT completion. The intervention includes: self-monitoring of symptoms, continued practice of TFT skills, engagement in meaningful activities, goal setting, and therapist support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: The comparison condition will be TAU following completion of TFT. In the spirit of TAU, providers will not be restricted in the type or intensity of services offered. Depending on local clinic policy or norms, providers randomized to TFT may provide post-TFT treatment themselves or Veterans may be referred to other providers and/or back to the clinician who referred the Veteran to TFT. If providers would have typically discharged Veterans following TFT, that is also allowable.
Study: NCT04322669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pidotimod
Description: Participants will be randomized in ratio of 1:1 to receive Pidotimod 400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
Study: NCT04661137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22
Study: NCT05867134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Removal of postoperative lifting restrictions
Description: Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to return to activity as tolerated/comfortable and stop activity if pain present.
Study: NCT06074783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)
Description: 50 x 106 allogeneic BM-derived MSCs formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under state of the art way of application that is ultrasound guidance which will ensure precise delivery of the BM derived MSCs at the site of injury or degeneration along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury or degeneration is not feasible.
Study: NCT06602258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: E2814 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: E2814 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: E2814 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: E2814 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV infusion.
Study: NCT06677710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-023
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-023
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Anti-CD20 antibody therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Anti-CD20 antibody therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Chemoprotectant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Chemoprotectant
Study: NCT06544096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group (WeChat platform + healthcare)
Description: When the parturients are discharged from the hospital, the medical staff of the intervention group will give the parturient health education about the discharge of the newborn, and the content of the education is the same as that of the control group. At the same time, the medical staff of the intervention group will introduce the usage and functions of the neonatal home skin care management system under the service of WeChat platform+health care to the parturient, and the system regularly pushes home care measures for common skin problems of newborns to their parents in different periods according to their birth dates.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group (routine health education)
Description: When the parturient is discharged from the hospital, the medical staff of the control unit will give the parturient health education about the discharge of the newborn. The contents of the education include neonatal jaundice, umbilical care, vaccination, 42-day follow-up, breastfeeding and so on, which are not included in the system.
Study: NCT05896670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: licaminlimab
Description: ophthalmic solution 60 mg/mL Subjects will receive licaminlimab eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of OCS-02
Description: inert ophthalmic solution vehicle of OCS-02 Subjects will receive vehicle eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
Study: NCT06618794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recovery Legal Care
Description: These patients will receive support from our HVIP standard of care (Violence Recovery Program) plus our Medical Legal Partnership (Recovery Legal Care) for additional legal support to address health-harming legal needs and public benefits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVIP Standard of Care
Description: These patients will receive HVIP standard of care (Violence Recovery Program Support)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVIP Standard of Care
Description: These patients will receive HVIP standard of care (Violence Recovery Program Support)
Study: NCT06617858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMB-05X
Description: Given by IV
Study: NCT06618755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group : PSH (usual care) with motivational interviewing
Description: The experimental group will begin follow-up after the 1st inclusion visit, during hospitalisation for withdrawal. The first motivational interview will take place 1 to 4 days before discharge from full hospitalisation. The following 10 motivational interviews will be held 2 weeks apart and will follow a framework based on the following objectives: to create a relationship of trust and an effective and lasting therapeutic alliance from the first interview; to create personalised objectives for the user, in line with their addictive pathology; to support the user as they modify, 'fail' and 'succeed' in achieving these objectives; to encourage the emergence and maintenance of the user's desire to change.
Study: NCT06675357

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FAPI
Description: 5 +/- 2 mCi of Ga-FAPI-46

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan
Study: NCT06680141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: control group
Study: NCT06679946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vutrisiran
Description: Vutrisiran administered SC q3M
Study: NCT06484400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) is a well-established psychological treatment that focuses on identifying, understanding, and changing negative thinking and behavior patterns. The intervention involves structured sessions where participants are taught strategies to alter detrimental thoughts and behaviors to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, CBT will be delivered in 12 one-hour weekly sessions conducted in person and on a one-on-one basis. This intervention is designed to reduce symptoms of depression and anxiety through cognitive restructuring and behavioral adaptations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ericksonian Hypnotehrapy
Description: Ericksonian Hypnotherapy is a form of psychotherapy using clinical hypnosis and indirect suggestion to modify unconscious behaviors and thought patterns. Named after Dr. Milton H. Erickson, this therapeutic approach emphasizes adaptability and utilizes the patient's own experiences and internal resources for healing. The therapy is known for its effectiveness in addressing anxiety and depression by encouraging flexibility in perception and behavior. Like CBT, this intervention will be administered over 12 one-hour sessions, each conducted in person and tailored to the individual's unique psychological landscape.
Study: NCT05104983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: The investigational drug product to be used in this study is sirolimus, provided in oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06622109

Intervention type: BIOLOGICAL
Intervention: 20-valent Pneumococcal Conjugate Vaccine
Description: Injection in the muscle or subcutaneous , 1 dose 0.5mL
Study: NCT06678659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-1245
Description: REC-1245 capsule 1mg, 5mg, 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-1245
Description: REC-1245 capsule 1mg, 5mg, 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-1245
Description: REC-1245 capsule 1mg, 5mg, 25mg
Study: NCT06681103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: Those participating in this condition will receive a personalised brief report which summarises the results of their initial assessment. The PONF will comprise the following elements: (1) Details of the main gambling and trading activities performed, including frequency of engagement and amount of money spent; (2) Scores on the criteria of pathological trading and/or PGSI (pathological gambling), together with an interpretation of the results and the level of severity; (3) Summary of the areas (financial, emotional, etc.) that the participant has indicated as being affected by gambling or trading. All results will be accompanied by graphs enabling participants to compare their scores with the average scores of the Spanish population of the same sex and age range. To prevent an increase in behaviour in participants whose frequency or intensity of gambling/trading is below the norm, as recommended by Newall et al. (2023), the normative data will include extreme averages and percentages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: Those participating in this condition will receive a personalised brief report which summarises the results of their initial assessment. The PONF will comprise the following elements: (1) Details of the main gambling and trading activities performed, including frequency of engagement and amount of money spent; (2) Scores on the criteria of pathological trading and/or PGSI (pathological gambling), together with an interpretation of the results and the level of severity; (3) Summary of the areas (financial, emotional, etc.) that the participant has indicated as being affected by gambling or trading. All results will be accompanied by graphs enabling participants to compare their scores with the average scores of the Spanish population of the same sex and age range. To prevent an increase in behaviour in participants whose frequency or intensity of gambling/trading is below the norm, as recommended by Newall et al. (2023), the normative data will include extreme averages and percentages
Study: NCT05327010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo diagnostic imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT06626308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brain functional MRI
Description: visual protocol stimulation during brain functional MRI
Study: NCT06624592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Subjects will receive standard of care anesthesia Sevoflurane, with intravenous push Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Subjects will receive standard of care anesthesia Isoflurane
Study: NCT06672939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06682858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy
Description: Participants will complete 8 group sessions of a CBT-based intervention designed to help self-regulate sensory difficulties in autistic young people